Search results
Showing 166 to 180 of 200 results for early or locally advanced breast cancer
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Discontinued Reference number: GID-TA11411
In development Reference number: GID-TA11089 Expected publication date: TBC
In development Reference number: GID-TA11273 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 1040.
Biographies and registered interests for members of the Technology Appraisal Committee A
Biographies and registered interests for members of the Technology Appraisal Committee A
In development Reference number: GID-TA11546 Expected publication date: TBC
Discontinued Reference number: GID-TA10028
Discontinued Reference number: GID-TA11339
This guidance has been updated and replaced by NICE technology appraisal guidance TA421.
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.